| 1 | Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis | 7.1 | 1 | Citations (PDF) |
| 2 | Posthospitalization COVID-19 cognitive deficits at 1 year are global and associated with elevated brain injury markers and gray matter volume reduction | 25.6 | 3 | Citations (PDF) |
| 3 | Myasthenia research over the last 50 years – a personal perspective | 0.1 | 0 | Citations (PDF) |
| 4 | Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses | 14.1 | 16 | Citations (PDF) |
| 5 | Neuroimmune disorders in COVID-19 | 3.4 | 38 | Citations (PDF) |
| 6 | Post-Infectious Autoimmunity in the Central (CNS) and Peripheral (PNS) Nervous Systems: An African Perspective | 5.0 | 10 | Citations (PDF) |
| 7 | Slow Channel Syndrome Revisited: 40 Years Clinical Follow-Up and Genetic Characterization of Two Cases | 2.8 | 1 | Citations (PDF) |
| 8 | Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis | 2.0 | 27 | Citations (PDF) |
| 9 | Systemic delivery of human GlyR IgG antibody induces GlyR internalization into motor neurons of brainstem and spinal cord with motor dysfunction in mice | 3.4 | 11 | Citations (PDF) |
| 10 | Relationship Between Serum NMDA Receptor Antibodies and Response to Antipsychotic Treatment in First-Episode Psychosis | 1.7 | 16 | Citations (PDF) |
| 11 | Autoantibodies in Japanese patients with ocular myasthenia gravis | 2.6 | 11 | Citations (PDF) |
| 12 | Neuronal surface antibodies are common in children with narcolepsy and active movement disorders | 2.0 | 2 | Citations (PDF) |
| 13 | Comparison of N-methyl-d-aspartate receptor antibody assays using live or fixed substrates | 3.4 | 9 | Citations (PDF) |
| 14 | Multimodal Biomarkers Quantify Recovery in Autoimmune Autonomic Ganglionopathy | 6.6 | 22 | Citations (PDF) |
| 15 | Systemic and cerebrospinal fluid immune and complement activation in Ugandan children and adolescents with long‐standing nodding syndrome: A case‐control study | 2.9 | 13 | Citations (PDF) |
| 16 | Using AChR antibody titres to predict treatment responses in myasthenia gravis | 2.0 | 5 | Citations (PDF) |
| 17 | Inhibition of Maternal-to-Fetal Transfer of IgG Antibodies by FcRn Blockade in a Mouse Model of Arthrogryposis Multiplex Congenita | 7.1 | 7 | Citations (PDF) |
| 18 | Antibodies to neuronal surface antigens in patients with a clinical diagnosis of neurodegenerative disorder | 4.3 | 19 | Citations (PDF) |
| 19 | MRI Patterns Distinguish AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disorder From Multiple Sclerosis | 2.5 | 14 | Citations (PDF) |
| 20 | Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis | 4.5 | 23 | Citations (PDF) |
| 21 | The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis | 1.0 | 4 | Citations (PDF) |
| 22 | Myasthenia Gravis and Related Disorders 2020, , 1011-1033 | | 1 | Citations (PDF) |
| 23 | Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin | 9.0 | 264 | Citations (PDF) |
| 24 | Paediatric myasthenia gravis: Prognostic factors for drug free remission | 0.7 | 23 | Citations (PDF) |
| 25 | SHP2 inhibitor protects AChRs from effects of myasthenia gravis MuSK antibody | 7.1 | 12 | Citations (PDF) |
| 26 | The Structure, Function, and Physiology of the Fetal and Adult Acetylcholine Receptor in Muscle | 3.5 | 53 | Citations (PDF) |
| 27 | Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis | 8.3 | 17 | Citations (PDF) |
| 28 | Myasthenia Gravis With Antibodies Against Muscle Specific Kinase: An Update on Clinical Features, Pathophysiology and Treatment | 3.5 | 29 | Citations (PDF) |
| 29 | Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis | 7.7 | 42 | Citations (PDF) |
| 30 | The Neuromuscular Junction in Health and Disease: Molecular Mechanisms Governing Synaptic Formation and Homeostasis | 3.5 | 119 | Citations (PDF) |
| 31 | Autoantibodies to the N-Methyl-D-Aspartate Receptor in Adolescents With Early Onset Psychosis and Healthy Controls | 2.7 | 6 | Citations (PDF) |
| 32 | Neuronal antibody prevalence in children with seizures under 3 years | 1.3 | 12 | Citations (PDF) |
| 33 | Maternal-Autoantibody-Related (MAR) Autism: Identifying Neuronal Antigens and Approaching Prospects for Intervention | 2.6 | 11 | Citations (PDF) |
| 34 | Maternal Immunity in Autism Spectrum Disorders: Questions of Causality, Validity, and Specificity | 2.6 | 11 | Citations (PDF) |
| 35 | Disentangling etiologies of CNS infections in Singapore using multiple correspondence analysis and random forest | 3.7 | 6 | Citations (PDF) |
| 36 | Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs | 2.0 | 16 | Citations (PDF) |
| 37 | Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study | 2.4 | 22 | Citations (PDF) |
| 38 | ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System | 2.5 | 21 | Citations (PDF) |
| 39 | In vivo Mechanisms of Antibody-Mediated Neurological Disorders: Animal Models and Potential Implications | 2.5 | 17 | Citations (PDF) |
| 40 | Relapse Patterns in NMOSD: Evidence for Earlier Occurrence of Optic Neuritis and Possible Seasonal Variation | 2.5 | 33 | Citations (PDF) |
| 41 | The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findingsBrain, 2020, 143, 3104-3120 | 8.9 | 859 | Citations (PDF) |
| 42 | Minimal manifestation status and prednisone withdrawal in the MGTX trial | 1.3 | 18 | Citations (PDF) |
| 43 | Autoimmune psychosis – Authors' reply | 9.0 | 4 | Citations (PDF) |
| 44 | The clinical profile of NMOSD in Australia and New Zealand | 3.4 | 21 | Citations (PDF) |
| 45 | Case report: Headache and neurological deficits with CSF lymphocytosis (HaNDL) associated with P/Q type voltage-gated calcium channel antibodies (<i>CACNA1A</i>) | 4.4 | 7 | Citations (PDF) |
| 46 | Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohortBrain, 2019, 142, 2303-2318 | 8.9 | 292 | Citations (PDF) |
| 47 | Autoimmune Encephalitis 2019, , 21-43 | | 0 | Citations (PDF) |
| 48 | Glycine receptor autoantibodies disrupt inhibitory neurotransmissionBrain, 2019, 142, 3398-3410 | 8.9 | 61 | Citations (PDF) |
| 49 | AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD | 2.5 | 65 | Citations (PDF) |
| 50 | O10.3. EXPOSURE TO COMMON INFECTIOUS PATHOGENS IN SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS: CLINICAL AND IMMUNOBIOLOGICAL ASSOCIATIONS | 4.3 | 0 | Citations (PDF) |
| 51 | Antibodies to neuronal surface proteins in Tourette Syndrome: Lack of evidence in a European paediatric cohort | 4.3 | 18 | Citations (PDF) |
| 52 | Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial | 19.1 | 164 | Citations (PDF) |
| 53 | Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line | 3.2 | 14 | Citations (PDF) |
| 54 | Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up | 2.0 | 39 | Citations (PDF) |
| 55 | Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodiesBrain, 2019, 142, 2000-2012 | 8.9 | 38 | Citations (PDF) |
| 56 | Searching for Serum Antibodies to Neuronal Proteins in Patients With Myalgic Encephalopathy/Chronic Fatigue Syndrome | 2.9 | 10 | Citations (PDF) |
| 57 | False-positive acetylcholine receptor antibody results in patients without myasthenia gravis | 2.4 | 18 | Citations (PDF) |
| 58 | In vitro neuronal network activity as a new functional diagnostic system to detect effects of Cerebrospinal fluid from autoimmune encephalitis patients | 3.7 | 7 | Citations (PDF) |
| 59 | Acquired neuromyotonia in children with <scp>CASPR</scp>2 and <scp>LGI</scp>1 antibodies | 3.9 | 19 | Citations (PDF) |
| 60 | GP230 Fetal acetylcholine receptor inactivation due to maternal myasthenia gravis: an underrecognised, devastating but potentially preventable and treatable disorder 2019, , A124.1-A124 | | 0 | Citations (PDF) |
| 61 | Muscle acetylcholine receptor conversion into chloride conductance at positive potentials by a single mutation | 7.7 | 4 | Citations (PDF) |
| 62 | Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients | 5.5 | 42 | Citations (PDF) |
| 63 | Immune or Genetic-Mediated Disruption of CASPR2 Causes Pain Hypersensitivity Due to Enhanced Primary Afferent Excitability | 12.8 | 124 | Citations (PDF) |
| 64 | Autoimmune neurological disorders-does the age matter? | 2.1 | 3 | Citations (PDF) |
| 65 | Serological and experimental studies in different forms of myasthenia gravis | 4.5 | 47 | Citations (PDF) |
| 66 | The importance of early immunotherapy in patients with faciobrachial dystonic seizuresBrain, 2018, 141, 348-356 | 8.9 | 300 | Citations (PDF) |
| 67 | Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases 2018, , 153-168 | | 2 | Citations (PDF) |
| 68 | Acquired Neuromyotonia 2018, , 239-250 | | 0 | Citations (PDF) |
| 69 | Movement disorders with neuronal antibodies: syndromic approach, genetic parallels and pathophysiology | 8.9 | 162 | Citations (PDF) |
| 70 | Brain-relevant antibodies in first-episode psychosis: a matched case–control study | 4.6 | 20 | Citations (PDF) |
| 71 | Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody | 4.1 | 11 | Citations (PDF) |
| 72 | Antibody-mediated central nervous system diseases | 1.8 | 11 | Citations (PDF) |
| 73 | NMDA-receptor antibodies alter cortical microcircuit dynamics | 7.7 | 39 | Citations (PDF) |
| 74 | Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia | 14.3 | 46 | Citations (PDF) |
| 75 | Investigation of neuronal auto-antibodies in children diagnosed with epileptic encephalopathy of unknown cause | 1.3 | 14 | Citations (PDF) |
| 76 | Glutamate receptor δ2 serum antibodies in pediatric opsoclonus myoclonus ataxia syndrome | 1.3 | 43 | Citations (PDF) |
| 77 | Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes | 2.0 | 30 | Citations (PDF) |
| 78 | Antiglycine receptor antibody related disease: a case series and literature review | 3.7 | 56 | Citations (PDF) |
| 79 | Do we need to measure specific antibodies in patients with limbic encephalitis? | 1.3 | 10 | Citations (PDF) |
| 80 | Pediatric Autoimmune Epileptic Encephalopathies | 1.8 | 12 | Citations (PDF) |
| 81 | First reported cases of anti-NMDA receptor encephalitis in Vietnamese adolescents and adults | 1.4 | 17 | Citations (PDF) |
| 82 | Recurrent Optic Neuritis Associated With MOG Antibody Seropositivity | 1.1 | 12 | Citations (PDF) |
| 83 | IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG | 7.1 | 57 | Citations (PDF) |
| 84 | Redefining progressive encephalomyelitis with rigidity and myoclonus after the discovery of antibodies to glycine receptors | 4.1 | 39 | Citations (PDF) |
| 85 | Antibodies Against Hypocretin Receptor 2 Are Rare in Narcolepsy | 0.8 | 33 | Citations (PDF) |
| 86 | CASPR2 autoantibodies are raised during pregnancy in mothers of children with mental retardation and disorders of psychological development but not autism | 2.0 | 38 | Citations (PDF) |
| 87 | Incidence and prevalence of NMOSD in Australia and New Zealand | 2.0 | 103 | Citations (PDF) |
| 88 | Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosisBrain, 2017, 140, 617-627 | 8.9 | 222 | Citations (PDF) |
| 89 | Diagnostic algorithm for relapsing acquired demyelinating syndromes in children | 1.3 | 161 | Citations (PDF) |
| 90 | Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitisBrain, 2017, 140, 1212-1219 | 8.9 | 90 | Citations (PDF) |
| 91 | Prevalence and clinical characteristics of serum neuronal cell surface antibodies in first-episode psychosis: a case-control study | 9.0 | 146 | Citations (PDF) |
| 92 | Paraneoplastic cerebellar degeneration and lambert‐eaton myasthenia in a patient with merkel cell carcinoma and voltage‐gated calcium channel antibodies | 2.6 | 11 | Citations (PDF) |
| 93 | IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients | 6.8 | 99 | Citations (PDF) |
| 94 | High sensitivity and specificity in proposed clinical diagnostic criteria for anti‐<i>N</i>‐methyl‐<scp>D</scp>‐aspartate receptor encephalitis | 3.9 | 45 | Citations (PDF) |
| 95 | Detection of NMDARs Antibodies in Encephalitis | 0.0 | 4 | Citations (PDF) |
| 96 | Persistent microglial activation and synaptic loss with behavioral abnormalities in mouse offspring exposed to CASPR2-antibodies in utero | 7.9 | 48 | Citations (PDF) |
| 97 | Pathogenic potential of antibodies to the <scp>GABA<sub>B</sub></scp> receptor | 2.9 | 33 | Citations (PDF) |
| 98 | 1633 Linear- versus conformational-protein directed autoantibodies in neuropsychiatric systemic lupus erythematosis | 2.0 | 0 | Citations (PDF) |
| 99 | Cell- and Single Molecule-Based Methods to Detect Anti- N -Methyl-D-Aspartate Receptor Autoantibodies in Patients With First-Episode Psychosis From the OPTiMiSE Project | 1.7 | 67 | Citations (PDF) |
| 100 | Focal status epilepticus and progressive dyskinesia: A novel phenotype for glycine receptor antibody-mediated neurological disease in children | 2.1 | 15 | Citations (PDF) |
| 101 | Pitfalls in the detection of N -methyl- d -aspartate-receptor (NMDA-R) antibodies | 1.8 | 15 | Citations (PDF) |
| 102 | Clinical presentation and prognosis in MOG-antibody disease: a UK studyBrain, 2017, 140, 3128-3138 | 8.9 | 567 | Citations (PDF) |
| 103 | Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease | 5.1 | 39 | Citations (PDF) |
| 104 | Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms | 0.6 | 143 | Citations (PDF) |
| 105 | Progress in autoimmune epileptic encephalitis | 4.1 | 19 | Citations (PDF) |
| 106 | Characteristics Of acetylcholine‐receptor‐antibody–negative myasthenia gravis in a South African cohort | 2.6 | 33 | Citations (PDF) |
| 107 | Autoantibodies and pain | 1.8 | 11 | Citations (PDF) |
| 108 | Anti-N-Methyl-D-Aspartate Receptor Encephalitis In A Young Child With Histological Evidence On Brain Biopsy Of Coexistent Herpes Simplex Virus Type 1 Infection | 1.3 | 15 | Citations (PDF) |
| 109 | Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies | 3.9 | 29 | Citations (PDF) |
| 110 | <i>N</i>‐methyl‐<scp>d</scp>‐aspartate (<scp>NMDA</scp>) receptor antibodies encephalitis mimicking an autistic regression | 3.9 | 32 | Citations (PDF) |
| 111 | <i>I</i>mmuno<i>g</i>lobuli<i>N</i><i>i</i>n the<i>T</i>reatment of<i>E</i>ncephalitis (IgNiTE): protocol for a multicentre randomised controlled trial | 2.0 | 19 | Citations (PDF) |
| 112 | Stiff person syndrome in South Asia | 1.6 | 4 | Citations (PDF) |
| 113 | Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica | 2.0 | 221 | Citations (PDF) |
| 114 | The Importance of Keeping in Mind the Diagnosis of N -Methyl-D-Aspartate Receptor Encephalitis | 1.7 | 1 | Citations (PDF) |
| 115 | Autoimmunity in neuropsychiatric disorders | 0.0 | 12 | Citations (PDF) |
| 116 | Autoimmune movement disorders | 0.0 | 16 | Citations (PDF) |
| 117 | Introduction to autoimmune neurology | 0.0 | 16 | Citations (PDF) |
| 118 | Voltage-gated potassium channel–complex autoimmunity and associated clinical syndromes | 0.0 | 45 | Citations (PDF) |
| 119 | Neuromuscular junction disorders | 0.0 | 51 | Citations (PDF) |
| 120 | Randomized Trial of Thymectomy in Myasthenia Gravis | 25.5 | 708 | Citations (PDF) |
| 121 | Compromised fidelity of B‐cell tolerance checkpoints in AChR and MuSK myasthenia gravis | 3.8 | 42 | Citations (PDF) |
| 122 | Neuronal antibodies in pediatric epilepsy: Clinical features and long‐term outcomes of a historical cohort not treated with immunotherapy | 4.8 | 33 | Citations (PDF) |
| 123 | Postencephalitic epilepsy and drug‐resistant epilepsy after infectious and antibody‐associated encephalitis in childhood: Clinical and etiologic risk factors | 4.8 | 56 | Citations (PDF) |
| 124 | Neuroimaging in encephalitis: analysis of imaging findings and interobserver agreement | 1.1 | 48 | Citations (PDF) |
| 125 | Autoimmune synaptopathies | 10.0 | 79 | Citations (PDF) |
| 126 | Salbutamol-responsive fetal acetylcholine receptor inactivation syndrome | 1.3 | 10 | Citations (PDF) |
| 127 | Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: Table 1 | 2.0 | 7 | Citations (PDF) |
| 128 | A clinical approach to diagnosis of autoimmune encephalitis | 19.1 | 2,944 | Citations (PDF) |
| 129 | Antibodies to AMPA receptors in Rasmussen's encephalitis | 2.1 | 19 | Citations (PDF) |
| 130 | Neuronal autoantibodies in epilepsy patients with peri-ictal autonomic findings | 3.4 | 41 | Citations (PDF) |
| 131 | Pregnancy outcomes in aquaporin-4–positive neuromyelitis optica spectrum disorder | 1.3 | 97 | Citations (PDF) |
| 132 | N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness | 1.7 | 6 | Citations (PDF) |
| 133 | Autoantibody-associated autoimmune-encephalitis in Sri Lankan patients | 1.4 | 0 | Citations (PDF) |
| 134 | Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study | 2.5 | 29 | Citations (PDF) |
| 135 | Fetal acetylcholine receptor inactivation syndrome | 7.1 | 57 | Citations (PDF) |
| 136 | Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases | 4.1 | 53 | Citations (PDF) |
| 137 | Antibodies to GABA
<sub>A</sub>
receptor α1 and γ2 subunits | 1.3 | 163 | Citations (PDF) |
| 138 | Epileptogenic effects of NMDAR antibodies in a passive transfer mouse modelBrain, 2015, 138, 3159-3167 | 8.9 | 92 | Citations (PDF) |
| 139 | Aquaporin-4 antibody isoform binding specificities do not explain clinical variations in NMO | 7.1 | 14 | Citations (PDF) |
| 140 | Central nervous system antibody-mediated diseases with autonomic involvement – Focus on VGKC-complex (LGI1, CASPR2), NMDAR and GlyR antibodies | 3.3 | 1 | Citations (PDF) |
| 141 | Neuronal antibodies in patients with suspected or confirmed sporadic Creutzfeldt-Jakob disease: Table 1 | 2.0 | 44 | Citations (PDF) |
| 142 | Collagen Q – A potential target for autoantibodies in myasthenia gravis | 1.4 | 46 | Citations (PDF) |
| 143 | Clinical relevance of serum antibodies to extracellular<i>N</i>-methyl-d-aspartate receptor epitopes | 2.0 | 95 | Citations (PDF) |
| 144 | Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: Table 1 | 2.0 | 95 | Citations (PDF) |
| 145 | Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model—Recommendations for methods and experimental designs | 4.1 | 27 | Citations (PDF) |
| 146 | Prevalence Rate of N-methyl-d-aspartate (NMDA) Receptor Antibodies in First Episode Psychosis. | 0.3 | 4 | Citations (PDF) |
| 147 | OP87 – 3001: Paediatric neurological syndromes associated with glycine receptor antibodies | 2.1 | 0 | Citations (PDF) |
| 148 | Paraneoplastic neurologic disorders in small cell lung carcinoma | 1.3 | 108 | Citations (PDF) |
| 149 | Guidelines for pre-clinical animal and cellular models of MuSK-myasthenia gravis | 4.1 | 27 | Citations (PDF) |
| 150 | Targeting the Interleukin 6 Receptor to Treat Neuromyelitis Optica | 14.3 | 4 | Citations (PDF) |
| 151 | Autoimmune Encephalopathies | 1.5 | 23 | Citations (PDF) |
| 152 | Clinical Features and Diagnostic Usefulness of Antibodies to Clustered Acetylcholine Receptors in the Diagnosis of Seronegative Myasthenia Gravis | 14.3 | 127 | Citations (PDF) |
| 153 | Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children | 7.1 | 192 | Citations (PDF) |
| 154 | Infectious and Autoantibody-Associated Encephalitis: Clinical Features and Long-term Outcome | 4.1 | 117 | Citations (PDF) |
| 155 | MOG cell-based assay detects non-MS patients with inflammatory neurologic disease | 7.1 | 335 | Citations (PDF) |
| 156 | Reduction in Serum Aquaporin-4 Antibody Titers During Development of a Tumor-Like Brain Lesion in a Patient With Neuromyelitis Optica: A Serum Antibody–Consuming Effect? | 1.9 | 6 | Citations (PDF) |
| 157 | N-methyl-D-aspartate receptor antibody-mediated neurological disease: results of a UK-based surveillance study in children | 1.6 | 109 | Citations (PDF) |
| 158 | Neuromyelitis optica in a child with Aicardi-GoutiÈres syndrome | 1.3 | 21 | Citations (PDF) |
| 159 | Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS | 7.1 | 200 | Citations (PDF) |
| 160 | GLYCINE RECEPTOR ANTIBODY—A MARKER FOR NMO/ NON-MS DEMYELINATION? | 2.0 | 0 | Citations (PDF) |
| 161 | A PROSPECTIVE CLINICAL AND IMMUNOLOGICAL STUDY OF LATE ONSET MYASTHENIA GRAVIS | 2.0 | 0 | Citations (PDF) |
| 162 | Neuroinflammation: Ways in Which the Immune System Affects the Brain | 6.5 | 188 | Citations (PDF) |
| 163 | Clinical relevance of voltage-gated potassium channel–complex antibodies in children | 1.3 | 56 | Citations (PDF) |
| 164 | Pediatric Herpes Simplex Virus Encephalitis Complicated by N-Methyl-D-aspartate Receptor Antibody Encephalitis | 1.5 | 22 | Citations (PDF) |
| 165 | Antibody-Mediated Autoimmune Encephalopathies and Immunotherapies | 6.5 | 71 | Citations (PDF) |
| 166 | Myasthenia gravis: a clinical-immunological update | 3.4 | 134 | Citations (PDF) |
| 167 | Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up | 3.4 | 37 | Citations (PDF) |
| 168 | Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination | 2.5 | 20 | Citations (PDF) |
| 169 | Low Levels of Vitamin D in Neuromyelitis Optica Spectrum Disorder: Association with Disease Disability | 2.5 | 33 | Citations (PDF) |
| 170 | Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort | 2.0 | 68 | Citations (PDF) |
| 171 | NMDA receptor antibodies associated with distinct white matter syndromes | 7.1 | 86 | Citations (PDF) |
| 172 | Voltage-Gated Potassium Channels Autoantibodies in a Child with Rasmussen Encephalitis | 1.2 | 9 | Citations (PDF) |
| 173 | RETROGRADE AMNESIA FOLLOWING AUTOIMMUNE LIMBIC ENCEPHALITIS | 2.0 | 0 | Citations (PDF) |
| 174 | VGKC-complex antibody encephalitis | 0.5 | 4 | Citations (PDF) |
| 175 | Gerstmann-Straüssler-Scheinker disease | 1.3 | 23 | Citations (PDF) |
| 176 | Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop | 2.2 | 22 | Citations (PDF) |
| 177 | Immunotherapy for patients with acute psychosis and serum N-Methyl d-Aspartate receptor (NMDAR) antibodies: A description of a treated case series | 2.4 | 58 | Citations (PDF) |
| 178 | EEG‐confirmed epileptic activity in a cat with VGKC‐complex/LGI1 antibody‐associated limbic encephalitis | 1.9 | 18 | Citations (PDF) |
| 179 | Advances in the clinical science of the motor unit | 4.1 | 0 | Citations (PDF) |
| 180 | PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY | 2.0 | 0 | Citations (PDF) |
| 181 | IgG and Complement Deposition and Neuronal Loss in Cats and Humans With Epilepsy and Voltage-Gated Potassium Channel Complex Antibodies | 1.9 | 40 | Citations (PDF) |
| 182 | AUTOANTIBODIES IN ALZHEIMER DISEASE; | 2.0 | 0 | Citations (PDF) |
| 183 | Features of Neuromyelitis Optica Spectrum Disorders and Aquaporin-4 With Myelin-Oligodendrocyte Glycoprotein Antibodies—Reply | 14.3 | 15 | Citations (PDF) |
| 184 | How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia | 1.6 | 95 | Citations (PDF) |
| 185 | The role of muscle‐specific tyrosine kinase (<scp>MuSK</scp>) and mystery of <scp>MuSK</scp> myasthenia gravis | 1.8 | 41 | Citations (PDF) |
| 186 | Characterisation of a syndrome of autoimmune adult onset focal epilepsy and encephalitis | 1.7 | 16 | Citations (PDF) |
| 187 | Long-term remission with rituximab in refractory leucine-rich glioma inactivated 1 antibody encephalitis | 2.4 | 28 | Citations (PDF) |
| 188 | Investigation of neuronal autoantibodies in two different focal epilepsy syndromes | 4.8 | 61 | Citations (PDF) |
| 189 | Paraneoplastic cerebellar syndrome and sensory ganglionopathy with papillary thyroid carcinoma | 1.4 | 11 | Citations (PDF) |
| 190 | Myasthenia Gravis and Related Disorders 2014, , 777-791 | | 0 | Citations (PDF) |
| 191 | Hypoventilation in glycine-receptor antibody related progressive encephalomyelitis, rigidity and myoclonus | 1.7 | 14 | Citations (PDF) |
| 192 | N‐methyl‐D‐aspartate receptor antibody‐associated movement disorder without encephalopathy | 3.9 | 32 | Citations (PDF) |
| 193 | Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances | 19.1 | 374 | Citations (PDF) |
| 194 | Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies | 14.3 | 519 | Citations (PDF) |
| 195 | Do Neuronal Autoantibodies Cause Psychosis? A Neuroimmunological Perspective | 1.7 | 52 | Citations (PDF) |
| 196 | Longstanding complex regional pain syndrome is associated with activating autoantibodies against alpha-1a adrenoceptorsPain, 2014, 155, 2408-2417 | 4.6 | 72 | Citations (PDF) |
| 197 | Cell-surface neuronal antibodies in patients with Japanese encephalitis virus | 2.4 | 1 | Citations (PDF) |
| 198 | Glycine receptor antibody mediated Progressive Encephalomyelitis with Rigidity and Myoclonus (PERM): a rare but treatable neurological syndrome | 1.4 | 31 | Citations (PDF) |
| 199 | Complement activation in patients with neuromyelitis optica | 2.4 | 55 | Citations (PDF) |
| 200 | Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomesBrain, 2014, 137, 2178-2192 | 8.9 | 456 | Citations (PDF) |
| 201 | <i>N</i>‐methyl‐<i>D</i>‐aspartate receptor antibodies in post–herpes simplex virus encephalitis neurological relapse | 5.3 | 196 | Citations (PDF) |
| 202 | Autoantibodies at the neuromuscular junction – link to the central nervous system | 0.6 | 1 | Citations (PDF) |
| 203 | Cell‐surface central nervous system autoantibodies: Clinical relevance and emerging paradigms | 6.6 | 154 | Citations (PDF) |
| 204 | Glycine receptor antibodies in a boy with focal epilepsy and episodic behavioral disorder | 1.4 | 30 | Citations (PDF) |
| 205 | Anti-NMDAR encephalitis misdiagnosed as Hashimoto's encephalopathy | 2.1 | 18 | Citations (PDF) |
| 206 | Clinical relevance of positive voltage-gated potassium channel (VGKC)-complex antibodies: experience from a tertiary referral centre | 2.0 | 102 | Citations (PDF) |
| 207 | Limbic Encephalitis Associated With Elevated Antithyroid Antibodies | 1.8 | 12 | Citations (PDF) |
| 208 | Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population | 1.4 | 31 | Citations (PDF) |
| 209 | Epilepsy-related psychosis: A role for autoimmunity? | 2.0 | 22 | Citations (PDF) |
| 210 | Axonal dysfunction with voltage gated potassium channel complex antibodies | 4.1 | 14 | Citations (PDF) |
| 211 | Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy | 7.1 | 13 | Citations (PDF) |
| 212 | Guillain‐Barré syndrome associated with <scp>CASPR2</scp> antibodies: two paediatric cases | 3.8 | 16 | Citations (PDF) |
| 213 | Clinical and experimental studies of potentially pathogenic brain-directed autoantibodies: current knowledge and future directions | 3.4 | 31 | Citations (PDF) |
| 214 | An 11-year retrospective experience of antibodies against the voltage-gated potassium channel (VGKC) complex from a tertiary neurological centre | 3.4 | 34 | Citations (PDF) |
| 215 | Autoimmune Encephalitis—Antibody Targets and Their Potential Pathogenicity in Immunotherapy-responsive Syndromes | 0.1 | 1 | Citations (PDF) |
| 216 | GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction | 16.3 | 362 | Citations (PDF) |
| 217 | Long-term clinical course with voltage-gated potassium channel antibody in Morvan’s syndrome | 3.4 | 8 | Citations (PDF) |
| 218 | Autoantibodies in Sporadic Creutzfeldt-Jakob Disease | 14.3 | 34 | Citations (PDF) |
| 219 | Autoimmune myasthenia gravis | 0.0 | 18 | Citations (PDF) |
| 220 | CACNA1H antibodies associated with headache with neurological deficits and cerebrospinal fluid lymphocytosis (HaNDL) | 4.4 | 37 | Citations (PDF) |
| 221 | Prevalence, clinical features and treatment outcomes of patients with myasthenia gravis positive for antibodies to muscle-specific kinase in Thailand | 1.7 | 4 | Citations (PDF) |
| 222 | Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica | 1.4 | 34 | Citations (PDF) |
| 223 | Developments in autoimmune channelopathies | 7.1 | 26 | Citations (PDF) |
| 224 | Organic neuropsychiatry: a treatable cause of suicidal behaviour | 1.4 | 1 | Citations (PDF) |
| 225 | Symptomatic brain involvement as the initial manifestation of neuromyelitis optica | 1.7 | 9 | Citations (PDF) |
| 226 | Acute disseminated encephalomyelitis associated with positive voltage gated potassium channel complex antibody | 2.1 | 2 | Citations (PDF) |
| 227 | Neuromyelitis Optica IgG Causes Placental Inflammation and Fetal Death | 0.6 | 89 | Citations (PDF) |
| 228 | N-Methyl-d-aspartate receptor (NMDAR) antibodies in post herpes simplex virus encephalitis (HSVE) neurological relapse | 1.4 | 1 | Citations (PDF) |
| 229 | Survivin Blockade Sensitizes Rhabdomyosarcoma Cells for Lysis by Fetal Acetylcholine Receptor–Redirected T Cells | 3.6 | 16 | Citations (PDF) |
| 230 | Ion channels in genetic and acquired forms of epilepsy | 3.2 | 127 | Citations (PDF) |
| 231 | Autoimmune epilepsy in children: Case series and proposed guidelines for identification | 4.8 | 79 | Citations (PDF) |
| 232 | A pilot study on neurological manifestations and antibodies against antigens in children with hematological and other cancers | 2.1 | 4 | Citations (PDF) |
| 233 | Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeBrain, 2013, 136, 3151-3162 | 8.9 | 363 | Citations (PDF) |
| 234 | Progressive Encephalomyelitis With Rigidity and Myoclonus | 14.3 | 52 | Citations (PDF) |
| 235 | Narcolepsy and H1N1 vaccination | 2.8 | 20 | Citations (PDF) |
| 236 | Neuronal Surface and Glutamic Acid Decarboxylase Autoantibodies in Nonparaneoplastic Stiff Person Syndrome | 14.3 | 58 | Citations (PDF) |
| 237 | Creutzfeld-Jakob Disease—Reply | 14.3 | 1 | Citations (PDF) |
| 238 | Longitudinally Extensive Transverse Myelitis With and Without Aquaporin 4 Antibodies | 14.3 | 100 | Citations (PDF) |
| 239 | Paediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens | 2.0 | 220 | Citations (PDF) |
| 240 | Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy | 4.8 | 195 | Citations (PDF) |
| 241 | Immune-mediated pediatric epilepsies | 0.0 | 10 | Citations (PDF) |
| 242 | Guillain-Barré-like syndrome associated with lung adenocarcinoma and CASPR2 antibodies | 2.6 | 14 | Citations (PDF) |
| 243 | Autoantibodies to neuronal antigens in children with new‐onset seizures classified according to the revised <scp>ILAE</scp> organization of seizures and epilepsies | 4.8 | 52 | Citations (PDF) |
| 244 | MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters | 2.5 | 152 | Citations (PDF) |
| 245 | Acute Measles Encephalitis in Partially Vaccinated Adults | 2.5 | 16 | Citations (PDF) |
| 246 | Immunization against GAD Induces Antibody Binding to GAD-Independent Antigens and Brainstem GABAergic Neuronal Loss | 2.5 | 27 | Citations (PDF) |
| 247 | Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia | 2.0 | 102 | Citations (PDF) |
| 248 | 138 Differences in outcomes in neuromyelitis optica between a Japanese cohort and a predominantly Caucasian cohort from the UK | 2.0 | 0 | Citations (PDF) |
| 249 | 162 The association of two rare neurological diseases: a multicentre study of 16 patients with AChR antibody myasthenia gravis and AQP4 antibody neuromyelitis optica spectrum disorder | 2.0 | 0 | Citations (PDF) |
| 250 | Anti–Glutamic Acid Decarboxylase Limbic Encephalitis Without Epilepsy Evolving Into Dementia With Cerebellar Ataxia | 6.8 | 18 | Citations (PDF) |
| 251 | 0842 Myelin-oligodendrocyte glycoprotein antibody as a cause of acute disseminated encephalomyelitis with a neuromyelitis optica-like phenotype in adults | 2.0 | 0 | Citations (PDF) |
| 252 | Republished review: Autoantibody testing in encephalopathies | 1.9 | 1 | Citations (PDF) |
| 253 | Febrile Infection-Related Epilepsy Syndrome without Detectable Autoantibodies and Response to Immunotherapy: A Case Series and Discussion of Epileptogenesis in FIRES | 1.2 | 72 | Citations (PDF) |
| 254 | Antibody-mediated encephalitis: a treatable cause of schizophrenia | 2.3 | 92 | Citations (PDF) |
| 255 | Presence and Pathogenic Relevance of Antibodies to Clustered Acetylcholine Receptor in Ocular and Generalized Myasthenia Gravis | 6.8 | 121 | Citations (PDF) |
| 256 | Paediatric autoimmune encephalitis: evaluation of clinical features, laboratory investigations and outcome | 1.6 | 0 | Citations (PDF) |
| 257 | 094 Anti-NMDA receptor antibodies disrupt cortical network activity in vitro | 2.0 | 0 | Citations (PDF) |
| 258 | Authors' reply | 2.3 | 0 | Citations (PDF) |
| 259 | The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies | 1.3 | 17 | Citations (PDF) |
| 260 | New serological markers for the differential diagnosis of autoimmune limbic encephalitis<sup>1)</sup> | 0.3 | 3 | Citations (PDF) |
| 261 | Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and JapanBrain, 2012, 135, 1834-1849 | 8.9 | 357 | Citations (PDF) |
| 262 | More movements in neuroimmunologyBrain, 2012, 135, 3201-3202 | 8.9 | 3 | Citations (PDF) |
| 263 | Supranuclear gaze palsy in glycine receptor antibody‐positive progressive encephalomyelitis with rigidity and myoclonus | 5.3 | 22 | Citations (PDF) |
| 264 | Glycine receptor antibodies are detected in progressive encephalomyelitis with rigidity and myoclonus (PERM) but not in saccadic oscillations | 3.4 | 49 | Citations (PDF) |
| 265 | NMDA receptor autoantibodies in sporadic Creutzfeldt-Jakob disease | 3.4 | 44 | Citations (PDF) |
| 266 | End of the bed (end of the video) diagnosis: Figure 1 | 1.4 | 1 | Citations (PDF) |
| 267 | Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition | 2.0 | 250 | Citations (PDF) |
| 268 | Immunopathology of autoantibody-associated encephalitides: clues for pathogenesisBrain, 2012, 135, 1622-1638 | 8.9 | 574 | Citations (PDF) |
| 269 | Autoantibody testing in encephalopathies | 1.4 | 10 | Citations (PDF) |
| 270 | Fetal acetylcholine receptor inactivation syndrome and maternal myasthenia gravis: A case report | 0.7 | 20 | Citations (PDF) |
| 271 | Serologic diagnosis of NMO | 1.3 | 452 | Citations (PDF) |
| 272 | VGKC‐complex antibody mediated encephalitis presenting with psychiatric features and neuroleptic malignant syndrome – further expanding the phenotype | 3.9 | 13 | Citations (PDF) |
| 273 | A clinico‐radiological phenotype of voltage‐gated potassium channel complex antibody‐mediated disorder presenting with seizures and basal ganglia changes | 3.9 | 8 | Citations (PDF) |
| 274 | Antibodies identified by cell‐based assays in myasthenia gravis and associated diseases | 4.5 | 39 | Citations (PDF) |
| 275 | The search for new antigenic targets in myasthenia gravis | 4.5 | 76 | Citations (PDF) |
| 276 | Morvan's syndrome associated with antibodies to multiple components of the voltage-gated potassium channel complex | 1.4 | 23 | Citations (PDF) |
| 277 | Myasthenia gravis and neuromyelitis optica spectrum disorder | 1.3 | 181 | Citations (PDF) |
| 278 | Neutrophil protease inhibition reduces neuromyelitis optica–immunoglobulin G–induced damage in mouse brain | 6.6 | 153 | Citations (PDF) |
| 279 | Morvan syndrome: Clinical and serological observations in 29 cases | 6.6 | 492 | Citations (PDF) |
| 280 | Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects | 4.1 | 110 | Citations (PDF) |
| 281 | Anti-N-Methyl-d-aspartate-receptor encephalitis: Cognitive profile in two children | 2.1 | 19 | Citations (PDF) |
| 282 | Febrile infection-related epilepsy syndrome is not caused by SCN1A mutations | 1.9 | 11 | Citations (PDF) |
| 283 | Management of suspected viral encephalitis in children – Association of British Neurologists and British Paediatric Allergy, Immunology and Infection Group National Guidelines | 2.9 | 151 | Citations (PDF) |
| 284 | Limbic encephalitis in children and adolescents | 1.6 | 135 | Citations (PDF) |
| 285 | Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS | 17.1 | 215 | Citations (PDF) |
| 286 | Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China | 1.4 | 37 | Citations (PDF) |
| 287 | Limbic encephalitis presenting as a post-partum psychiatric condition | 1.4 | 8 | Citations (PDF) |
| 288 | Paroxysmal EEG pattern in a child with N-methyl-d-aspartate receptor antibody encephalitis | 3.9 | 20 | Citations (PDF) |
| 289 | Elevated VGKC-complex antibodies in a boy with fever-induced refractory epileptic encephalopathy in school-age children (FIRES) | 3.9 | 111 | Citations (PDF) |
| 290 | Immune-mediated steroid-responsive epileptic spasms and epileptic encephalopathy associated with VGKC-complex antibodies | 3.9 | 40 | Citations (PDF) |
| 291 | Human limbic encephalitis serum enhances hippocampal mossy fiber-CA3 pyramidal cell synaptic transmission | 4.8 | 90 | Citations (PDF) |
| 292 | Systemic and neurologic autoimmune disorders associated with seizures or epilepsy | 4.8 | 64 | Citations (PDF) |
| 293 | Potentially pathogenic autoantibodies associated with epilepsy and encephalitis in children and adults | 4.8 | 33 | Citations (PDF) |
| 294 | T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement | 2.4 | 32 | Citations (PDF) |
| 295 | Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Behçet's disease | 2.4 | 22 | Citations (PDF) |
| 296 | Autoimmunity against the β2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndromePain, 2011, 152, 2690-2700 | 4.6 | 162 | Citations (PDF) |
| 297 | Autoantibodies associated with diseases of the CNS: new developments and future challenges | 19.1 | 524 | Citations (PDF) |
| 298 | Surviving stiff-person syndrome: a case report | 3.4 | 3 | Citations (PDF) |
| 299 | Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica | 3.4 | 26 | Citations (PDF) |
| 300 | NMDA Receptor Antibody Encephalitis | 4.7 | 93 | Citations (PDF) |
| 301 | Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis | 6.6 | 749 | Citations (PDF) |
| 302 | Antiglycine-receptor encephalomyelitis with rigidity | 2.0 | 125 | Citations (PDF) |
| 303 | Neue serologische Marker zur Differentialdiagnose der Autoimmun-Enzephalitis/New serological markers for the differential diagnosis of autoimmune limbic encephalitis | 0.3 | 4 | Citations (PDF) |
| 304 | John Newsom-Davis: clinician-scientist and so much moreBrain, 2011, 134, 3755-3774 | 8.9 | 6 | Citations (PDF) |
| 305 | VGKC antibodies in pediatric encephalitis presenting with status epilepticus | 1.3 | 94 | Citations (PDF) |
| 306 | Progressive encephalomyelitis with rigidity and myoclonus: Resolution after thymectomy | 1.3 | 54 | Citations (PDF) |
| 307 | Progressive encephalomyelitis with rigidity and myoclonus | 1.3 | 97 | Citations (PDF) |
| 308 | Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative limbic encephalitis | 0.4 | 48 | Citations (PDF) |
| 309 | Autoimmune mediated neuromuscular junction defects | 4.1 | 70 | Citations (PDF) |
| 310 | Anti-N-methyl-D-aspartate receptor antibodies: A potentially treatable cause of encephalitis in the intensive care unit | 0.6 | 87 | Citations (PDF) |
| 311 | The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins | 4.1 | 99 | Citations (PDF) |
| 312 | N-methyl-D-aspartate limbic encephalitis: Diagnosis should respect well-recognized criteria | 0.6 | 1 | Citations (PDF) |
| 313 | Prospective Study into the Incidence of Lambert Eaton Myasthenic Syndrome in Small Cell Lung Cancer | 1.1 | 48 | Citations (PDF) |
| 314 | Caspr2 Antibodies in Patients with Thymomas | 1.1 | 59 | Citations (PDF) |
| 315 | Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis | 3.4 | 19 | Citations (PDF) |
| 316 | Autoimmune Channelopathies: Well-Established and Emerging Immunotherapy-Responsive Diseases of the Peripheral and Central Nervous Systems | 3.4 | 34 | Citations (PDF) |
| 317 | Anti-N-methyl-D-Aspartate-Receptor Encephalitis in a Four-Year-Old Girl | 2.1 | 19 | Citations (PDF) |
| 318 | Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis | 6.6 | 436 | Citations (PDF) |
| 319 | Autoantibodies to glutamic acid decarboxylase in patients with epilepsy are associated with low cortical GABA levels | 4.8 | 42 | Citations (PDF) |
| 320 | PAW33 Aquaporin-4 M 23 isoform provides a more sensitive assay for aquaporin-4 antibodies | 2.0 | 4 | Citations (PDF) |
| 321 | Successful treatment of antiN-methyl-d-aspartate receptor limbic encephalitis in a 22-monthold child with plasmapheresis and pharmacological immunomodulation | 1.6 | 35 | Citations (PDF) |
| 322 | The Association of Bullous Pemphigoid With Cerebrovascular Disease and Dementia | 2.2 | 107 | Citations (PDF) |
| 323 | Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in miceBrain, 2010, 133, 349-361 | 8.9 | 463 | Citations (PDF) |
| 324 | Successful 'passive transfer' of paraneoplastic stiff person syndrome with antibodies to an intracellular antigenBrain, 2010, 133, 3164-3165 | 8.9 | 11 | Citations (PDF) |
| 325 | PATU1 Characteristic faciobrachial dystonic seizures as an immunotherapy-responsive prodrome to voltage-gated potassium channel antibody-associated limbic encephalitis | 2.0 | 0 | Citations (PDF) |
| 326 | Corticomotoneuronal function and hyperexcitability in acquired neuromyotoniaBrain, 2010, 133, 2727-2733 | 8.9 | 30 | Citations (PDF) |
| 327 | Interferon Beta Treatment in Neuromyelitis Optica | 6.8 | 282 | Citations (PDF) |
| 328 | Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis | 1.4 | 151 | Citations (PDF) |
| 329 | N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexesBrain, 2010, 133, 1655-1667 | 8.9 | 883 | Citations (PDF) |
| 330 | Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotoniaBrain, 2010, 133, 2734-2748 | 8.9 | 1,150 | Citations (PDF) |
| 331 | Anti-NMDA Receptor Encephalitis With Atypical Brain Changes on MRI | 1.9 | 15 | Citations (PDF) |
| 332 | Non-paraneoplastic limbic encephalitis characterized by mesio-temporal seizures and extratemporal lesions: A case report | 2.3 | 16 | Citations (PDF) |
| 333 | Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study | 15.7 | 1,097 | Citations (PDF) |
| 334 | Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients | 3.4 | 63 | Citations (PDF) |
| 335 | Disease-relevant autoantibodies in first episode schizophrenia | 3.4 | 271 | Citations (PDF) |
| 336 | Immunocapture and Identification of Cell Membrane Protein Antigenic Targets of Serum Autoantibodies | 4.8 | 8 | Citations (PDF) |
| 337 | ENDPLATE DESTRUCTION DUE TO MATERNAL ANTIBODIES IN ARTHROGRYPOSIS MULTIPLEX CONGENITA | 1.3 | 14 | Citations (PDF) |
| 338 | Successful treatment of anti-N-methyl-D-aspartate receptor encephalitis presenting with catatonia | 1.6 | 66 | Citations (PDF) |
| 339 | Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women With New-Onset Epilepsy | 6.8 | 151 | Citations (PDF) |
| 340 | N‐methyl‐<scp>D</scp>‐aspartate receptor antibodies in pediatric dyskinetic encephalitis lethargica | 6.6 | 213 | Citations (PDF) |
| 341 | Autoimmune disorders of the neuromuscular junction | 4.1 | 49 | Citations (PDF) |
| 342 | Immune-mediated rippling muscle disease with myasthenia gravis: A report of seven patients with long-term follow-up in two | 0.7 | 39 | Citations (PDF) |
| 343 | MuSK-antibody-positive myasthenia gravis in a South Asian population | 1.4 | 16 | Citations (PDF) |
| 344 | The Effect of Plasma From Muscle-Specific Tyrosine Kinase Myasthenia Patients on Regenerating Endplates | 3.6 | 35 | Citations (PDF) |
| 345 | Anti‐NMDA receptor encephalitis: a video case report | 1.9 | 9 | Citations (PDF) |
| 346 | Autoimmune channelopathies: new antibody-mediated disorders of the central nervous system | 2.5 | 11 | Citations (PDF) |
| 347 | Epitopes expressed in myasthenia gravis (MG) thymomas are not recognized by patients' T cells or autoantibodies | 3.5 | 4 | Citations (PDF) |
| 348 | Relative frequency of VGKC and ‘classical’ paraneoplastic antibodies in patients with limbic encephalitis | 3.4 | 23 | Citations (PDF) |
| 349 | New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin | 3.4 | 8 | Citations (PDF) |
| 350 | <i>Myasthenia Gravis Seronegative for Acetylcholine Receptor Antibodies</i> | 4.5 | 90 | Citations (PDF) |
| 351 | <i>Autoimmunizing Mechanisms in Thymoma and Thymus</i>* | 4.5 | 85 | Citations (PDF) |
| 352 | <i>Congenital Myasthenic Syndromes and the Formation of the Neuromuscular Junction</i> | 4.5 | 28 | Citations (PDF) |
| 353 | Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1 | 2.4 | 124 | Citations (PDF) |
| 354 | Autoimmune channelopathies: John Newsom-Davis's work and legacy | 2.4 | 10 | Citations (PDF) |
| 355 | CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis | 1.4 | 73 | Citations (PDF) |
| 356 | Autoantibodies in different forms of myasthenia gravis and in the Lambert–Eaton syndrome | 0.0 | 2 | Citations (PDF) |
| 357 | Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica | 1.5 | 286 | Citations (PDF) |
| 358 | Stiff, twitchy or wobbly—are GAD antibodies pathogenic?Brain, 2008, 131, 2536-2537 | 8.9 | 31 | Citations (PDF) |
| 359 | Aquaporin-4 Antibodies in Neuromyelitis Optica and Longitudinally Extensive Transverse Myelitis | 6.8 | 254 | Citations (PDF) |
| 360 | FETAL ACETYLCHOLINE RECEPTOR INACTIVATION SYNDROME AND MATERNAL MYASTHENIA GRAVIS | 1.3 | 44 | Citations (PDF) |
| 361 | PROGRESSIVE ENCEPHALOMYELITIS, RIGIDITY, AND MYOCLONUS: A NOVEL GLYCINE RECEPTOR ANTIBODY | 1.3 | 330 | Citations (PDF) |
| 362 | IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†Brain, 2008, 131, 1940-1952 | 8.9 | 416 | Citations (PDF) |
| 363 | Autoimmune disorders of the neuromuscular junction | 0.4 | 23 | Citations (PDF) |
| 364 | Autoantibodies in neuromuscular transmission disorders | 0.7 | 3 | Citations (PDF) |
| 365 | John Newsom-Davis, 1932–2007 | 1.5 | 0 | Citations (PDF) |
| 366 | Autoantibodies in patients with gut motility disorders and enteric neuropathy | 1.8 | 44 | Citations (PDF) |
| 367 | Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies | 1.0 | 36 | Citations (PDF) |
| 368 | Overexpression of Rapsyn in Rat Muscle Increases Acetylcholine Receptor Levels in Chronic Experimental Autoimmune Myasthenia Gravis | 3.6 | 33 | Citations (PDF) |
| 369 | Myasthenia Gravis Thymus | 3.6 | 110 | Citations (PDF) |
| 370 | Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system | 25.6 | 349 | Citations (PDF) |
| 371 | An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus | 40.1 | 161 | Citations (PDF) |
| 372 | Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures | 2.4 | 35 | Citations (PDF) |
| 373 | Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica | 8.1 | 182 | Citations (PDF) |
| 374 | MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravisBrain, 2006, 129, 1481-1492 | 8.9 | 160 | Citations (PDF) |
| 375 | MuSK antibody-positive, seronegative myasthenia gravis in Korea | 1.7 | 33 | Citations (PDF) |
| 376 | Autoimmune Channelopathies and Related Neurological Disorders | 12.8 | 96 | Citations (PDF) |
| 377 | Fetal arthrogryposis and maternal serum antibodies | 0.7 | 31 | Citations (PDF) |
| 378 | Use of Anti‐Nerve Antibodies 2006, , 87-93 | | 0 | Citations (PDF) |
| 379 | Antibodies to voltage-gated potassium and calcium channels in epilepsy | 1.9 | 124 | Citations (PDF) |
| 380 | A 45-year history of acquired autoimmune neuromyotonia | 3.4 | 1 | Citations (PDF) |
| 381 | Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: The role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test | 5.3 | 55 | Citations (PDF) |
| 382 | Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis | 2.6 | 55 | Citations (PDF) |
| 383 | Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis | 6.6 | 203 | Citations (PDF) |
| 384 | Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestationsBrain, 2006, 129, 1570-1584 | 8.9 | 139 | Citations (PDF) |
| 385 | Diverse molecular mechanisms involved in AChR deficiency due to rapsyn mutationsBrain, 2006, 129, 2773-2783 | 8.9 | 52 | Citations (PDF) |
| 386 | Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5 | 1.3 | 112 | Citations (PDF) |
| 387 | Dok-7 Mutations Underlie a Neuromuscular Junction Synaptopathy | 38.2 | 235 | Citations (PDF) |
| 388 | Rhabdomyosarcoma Lysis by T Cells Expressing a Human Autoantibody-Based Chimeric Receptor Targeting the Fetal Acetylcholine Receptor | 0.6 | 35 | Citations (PDF) |
| 389 | Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis | 4.1 | 126 | Citations (PDF) |
| 390 | Myasthenia gravis with MuSK antibodies | 1.4 | 6 | Citations (PDF) |
| 391 | Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels | 6.5 | 120 | Citations (PDF) |
| 392 | Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation | 2.4 | 24 | Citations (PDF) |
| 393 | Immune responses to Campylobacter and serum autoantibodies in patients with complex regional pain syndrome | 2.4 | 42 | Citations (PDF) |
| 394 | Anti-glial nuclear antibody: Marker of lung cancer-related paraneoplastic neurological syndromes | 2.4 | 117 | Citations (PDF) |
| 395 | MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo | 2.4 | 56 | Citations (PDF) |
| 396 | Acetylcholine receptors loss and postsynaptic damage in MuSK antibody–positive myasthenia gravis | 6.6 | 158 | Citations (PDF) |
| 397 | Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG | 6.6 | 209 | Citations (PDF) |
| 398 | Antibodies associated with paraneoplastic neurological disorders | 1.7 | 6 | Citations (PDF) |
| 399 | Patterns and severity of neuromuscular transmission failure in seronegative myasthenia gravis | 2.0 | 58 | Citations (PDF) |
| 400 | Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravisBrain, 2005, 128, 2327-2337 | 8.9 | 64 | Citations (PDF) |
| 401 | Autoimmune channelopathies | 1.5 | 62 | Citations (PDF) |
| 402 | Mechanisms in myasthenia gravis | 1.4 | 2 | Citations (PDF) |
| 403 | Seronegative Myasthenia Gravis | 2.0 | 78 | Citations (PDF) |
| 404 | A mouse model of AChR deficiency syndrome with a phenotype reflecting the human condition | 3.1 | 28 | Citations (PDF) |
| 405 | Encephalitis lethargica: part of a spectrum of post-streptococcal autoimmune diseases? | 8.9 | 33 | Citations (PDF) |
| 406 | Low-voltage-activated A-current controls the firing dynamics of mouse hypothalamic orexin neurons | 3.7 | 27 | Citations (PDF) |
| 407 | Detection and characterization of MuSK antibodies in seronegative myasthenia gravis | 6.6 | 386 | Citations (PDF) |
| 408 | Lack of association between acetylcholine receptor ? polymorphisms and early-onset myasthenia gravis | 2.6 | 7 | Citations (PDF) |
| 409 | Potassium channel antibody‐associated encephalopathy: a potentially immunotherapy‐responsive form of limbic encephalitisBrain, 2004, 127, 701-712 | 8.9 | 1,005 | Citations (PDF) |
| 410 | Distinct phenotypes of congenital acetylcholine receptor deficiency | 0.7 | 59 | Citations (PDF) |
| 411 | Myasthenia Gravis | 3.1 | 19 | Citations (PDF) |
| 412 | Serum autoantibodies to cell surface determinants in multiple sclerosis: a flow cytometric studyBrain, 2004, 127, 269-279 | 8.9 | 50 | Citations (PDF) |
| 413 | Chapter 16 Antibody-mediated disorders of neuromuscular transmission | 0.0 | 5 | Citations (PDF) |
| 414 | Structural Abnormalities of the AChR Caused by Mutations Underlying Congenital Myasthenic Syndromes | 4.5 | 6 | Citations (PDF) |
| 415 | Pathogenic Autoantibodies in the Lambert-Eaton Myasthenic Syndrome | 4.5 | 39 | Citations (PDF) |
| 416 | LEMS IgG Binds to Extracellular Determinants on N-Type Voltage-Gated Calcium Channels, but Does Not Reduce VGCC Expression | 4.5 | 6 | Citations (PDF) |
| 417 | Autoimmune Disorders of Neuronal Potassium Channels | 4.5 | 101 | Citations (PDF) |
| 418 | Antibodies in Myasthenia Gravis and Related Disorders | 4.5 | 98 | Citations (PDF) |
| 419 | Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets | 19.1 | 204 | Citations (PDF) |
| 420 | Maternal neuronal antibodies associated with autism and a language disorder | 6.6 | 178 | Citations (PDF) |
| 421 | Antibodies to Neuronal Targets in Neurological and Psychiatric Diseases | 4.5 | 16 | Citations (PDF) |
| 422 | Amnesia, cerebral atrophy, and autoimmunity | 35.3 | 39 | Citations (PDF) |
| 423 | Autoantibodies to ion channels at the neuromuscular junction | 7.1 | 49 | Citations (PDF) |
| 424 | Evidence of underdiagnosis of myasthenia gravis in older people | 2.0 | 174 | Citations (PDF) |
| 425 | Spontaneous production of anti-IFN- and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor | 3.4 | 65 | Citations (PDF) |
| 426 | Antibodies against Muscle-Specific Kinase in Juvenile Myasthenia Gravis | 1.2 | 4 | Citations (PDF) |
| 427 | New autoantibody mediated disorders of the central nervous system | 4.1 | 37 | Citations (PDF) |
| 428 | AChR phosphorylation and indirect inhibition of AChR function in seronegative MG | 1.3 | 66 | Citations (PDF) |
| 429 | Mutations in congenital myasthenic syndromes reveal an varepsilon subunit C-terminal cysteine, C470, crucial for maturation and surface expression of adult AChR | 3.1 | 41 | Citations (PDF) |
| 430 | Phenotypic variants of autoimmune peripheral nerve hyperexcitabilityBrain, 2002, 125, 1887-1895 | 8.9 | 407 | Citations (PDF) |
| 431 | A Role for Autoantibodies in Some Cases of Acquired Non-Paraneoplastic Gut Dysmotility | 1.8 | 39 | Citations (PDF) |
| 432 | Diseases of the neuromuscular junction | 4.1 | 32 | Citations (PDF) |
| 433 | Expression of foetal type acetylcholine receptor is restricted to type 1 muscle fibres in human neuromuscular disordersBrain, 2002, 125, 1309-1319 | 8.9 | 42 | Citations (PDF) |
| 434 | Reflections on the VIth International Congress of Neuroimmunology held at the Edinburgh International Conference Centre, Edinburgh, September 3–7, 2001 | 2.4 | 2 | Citations (PDF) |
| 435 | Maternal antibody-mediated dyslexia? Evidence for a pathogenic serum factor in a mother of two dyslexic children shown by transfer to mice using behavioural studies and magnetic resonance spectroscopy | 2.4 | 24 | Citations (PDF) |
| 436 | Measuring and evaluating the significance of autoantibodies in neurological disorders | 0.6 | 9 | Citations (PDF) |
| 437 | Antibodies to Acetylcholine Receptor in Parous Women with Myasthenia: Evidence for Immunization by Fetal Antigen | 3.5 | 40 | Citations (PDF) |
| 438 | Unravelling the pathogenesis of myasthenia gravis | 17.9 | 356 | Citations (PDF) |
| 439 | Myasthenia gravis: diagnostic and management dilemmas | 4.1 | 31 | Citations (PDF) |
| 440 | Stiff-Person Syndrome: Autoimmunity and the Central Nervous System | 0.7 | 19 | Citations (PDF) |
| 441 | Potassium channel antibodies in two patients with reversible limbic encephalitis | 6.6 | 367 | Citations (PDF) |
| 442 | Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies | 25.6 | 1,040 | Citations (PDF) |
| 443 | Presynaptic neuronal antigens expressed by a small cell lung carcinoma cell line | 2.4 | 56 | Citations (PDF) |
| 444 | Restricted IgG1 subclass of anti-Yo antibodies in paraneoplastic cerebellar degeneration | 2.4 | 26 | Citations (PDF) |
| 445 | Presentation by myoblasts of an epitope from endogenous acetylcholine receptor indicates a potential role in the spreading of the immune response | 2.4 | 36 | Citations (PDF) |
| 446 | Cerebellar Ataxia With Anti–Glutamic Acid Decarboxylase Antibodies | 6.8 | 362 | Citations (PDF) |
| 447 | End-plate gamma- and varepsilon-subunit mRNA levels in AChR deficiency syndrome due to varepsilon-subunit null mutationsBrain, 2001, 124, 1362-1372 | 8.9 | 48 | Citations (PDF) |
| 448 | Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channelsBrain, 2001, 124, 2417-2426 | 8.9 | 338 | Citations (PDF) |
| 449 | Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? | 1.3 | 96 | Citations (PDF) |
| 450 | Acetylcholine receptor δ subunit mutations underlie a fast-channel myasthenic syndrome and arthrogryposis multiplex congenita | 9.1 | 36 | Citations (PDF) |
| 451 | Asymptomatic maternal myasthenia as a cause of the Pena-Shokeir phenotype 2000, 92, 1-6 | | 58 | Citations (PDF) |
| 452 | The spectrum of mutations causing end-plate acetylcholinesterase deficiency | 6.6 | 114 | Citations (PDF) |
| 453 | Molecular targets for autoimmune and genetic disorders of neuromuscular transmission | 0.3 | 69 | Citations (PDF) |
| 454 | Neuroprotective autoimmunity—a double-edged sword? | 25.6 | 1 | Citations (PDF) |
| 455 | Persistent facial myokymia: an autoimmune aetiology? | 3.4 | 9 | Citations (PDF) |
| 456 | Autoantibodies in Thymoma-Associated Myasthenia Gravis With Myositis or Neuromyotonia | 6.8 | 81 | Citations (PDF) |
| 457 | Autoantibody screening in subacute cerebellar ataxia | 35.3 | 33 | Citations (PDF) |
| 458 | Neuromyotonia in association with essential thrombocythemia | 1.4 | 6 | Citations (PDF) |
| 459 | Neuromyotonia in association with systemic sclerosis | 3.4 | 11 | Citations (PDF) |
| 460 | Monoclonal antibodies raised against human acetylcholine receptor bind to all five subunits of the fetal isoform | 2.4 | 28 | Citations (PDF) |
| 461 | Pathogenic autoantibodies to neuronal proteins in neurological disorders | 2.4 | 44 | Citations (PDF) |
| 462 | Physicochemical and immunological studies of the N-terminal domain �of theTorpedoacetylcholine receptor α-subunit expressed in �Escherichia coli | 0.3 | 33 | Citations (PDF) |
| 463 | Immune-mediated peripheral neuropathies and voltage-gated sodiums channels 1999, 22, 108-110 | | 20 | Citations (PDF) |
| 464 | A Comparison of MyoD1 and Fetal Acetylcholine Receptor Expression in Childhood Tumors and Normal Tissues | 2.9 | 27 | Citations (PDF) |
| 465 | [36] Antibodies to ion channels | 1.0 | 0 | Citations (PDF) |
| 466 | Antibodies to Ion Channels in Paraneoplastic Disorders | 4.7 | 21 | Citations (PDF) |
| 467 | Immunology of the neuromuscular junction and presynaptic nerve terminal | 4.1 | 11 | Citations (PDF) |
| 468 | Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice | 9.1 | 69 | Citations (PDF) |
| 469 | Neuronal Staining Patterns in Sera from Patients with Lambert-Eaton Myasthenic Syndromea | 4.5 | 1 | Citations (PDF) |
| 470 | Evidence for an Association between Human Acetylcholine Receptor and Rapsyna | 4.5 | 4 | Citations (PDF) |
| 471 | A Single Nucleotide Deletion in the e Subunit of the Acetylcholine Receptor (AChR) in Five Congenital Myasthenic Syndrome Patients with AChR Deficiencya | 4.5 | 12 | Citations (PDF) |
| 472 | Expression of Muscle Proteins in Thymomas of Patients with Myasthenia Gravisa | 4.5 | 5 | Citations (PDF) |
| 473 | Antibodies Affecting Ion Channel Function in Acquired Neuromyotonia, in Seropositive and Seronegative Myasthenia Gravis, and in Antibody-mediated Arthrogryposis Multiplex Congenita | 4.5 | 41 | Citations (PDF) |
| 474 | Seronegative Myasthenia Plasmas and Non-IgG Fractions Transiently Inhibit nAChR Functiona | 4.5 | 8 | Citations (PDF) |
| 475 | An Animal Model of Maternal Antibodymediated Arthrogryposis Multiplex Congenita (AMC)a | 4.5 | 7 | Citations (PDF) |
| 476 | The Role of Autoantibodies in Lambert-Eaton Myasthenic Syndromeaa | 4.5 | 33 | Citations (PDF) |
| 477 | Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis | 6.8 | 93 | Citations (PDF) |
| 478 | IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody- mediated disease | 3.5 | 98 | Citations (PDF) |
| 479 | Induction of primary immune responses by allogeneic human myoblasts: dissection of the cell types required for proliferation, IFNγ secretion and cytotoxicity | 2.4 | 30 | Citations (PDF) |
| 480 | α -Bungarotoxin binding to human muscle acetylcholine receptor: measurement of affinity, delineation of AChR subunit residues crucial to binding, and protection of AChR function by synthetic peptides | 3.6 | 14 | Citations (PDF) |
| 481 | A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. | 9.1 | 72 | Citations (PDF) |
| 482 | Antibodies to 125I-glutamic acid decarboxylase in patients with stiff man syndrome. | 2.0 | 26 | Citations (PDF) |
| 483 | Postsynaptic Abnormalities at the Neuromuscular Junctions of Utrophin-deficient Mice | 4.8 | 205 | Citations (PDF) |
| 484 | Diverse Fab specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library | 3.4 | 45 | Citations (PDF) |
| 485 | Mutations in Different Functional Domains of the Human Muscle Acetylcholine Receptor Subunit in Patients with the Slow-Channel congenital Myasthenic Syndrome | 3.1 | 124 | Citations (PDF) |
| 486 | Mechanisms of Action of Anti‐GM<sub>1</sub>and Anti‐GQ<sub>1b</sub>Ganglioside Antibodies in Guillain‐Barré Syndrome | 4.0 | 38 | Citations (PDF) |
| 487 | Congenital myasthenic syndromes | 4.1 | 13 | Citations (PDF) |
| 488 | Disorders of the Human Neuromuscular Junction | 0.0 | 4 | Citations (PDF) |
| 489 | Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome | 1.4 | 228 | Citations (PDF) |
| 490 | Identification of phospholipase A2 and neurotoxic activities in the venom of the New Guinean small-eyed snake (Micropechis ikaheka) | 1.8 | 9 | Citations (PDF) |
| 491 | Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease | 35.3 | 94 | Citations (PDF) |
| 492 | Lack of effect of Miller Fisher sera/plasmas on transmitter release from PC12 cells | 2.4 | 7 | Citations (PDF) |
| 493 | Genes at the junction—candidates for congenital myasthenic syndromes | 13.4 | 55 | Citations (PDF) |
| 494 | Antibodies specific for fetal AChR induce arthrogryposis multiplex congenita in developing mice: an animal model for transfer of pathogenic antibodies | 1.1 | 0 | Citations (PDF) |
| 495 | Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia | 6.6 | 301 | Citations (PDF) |
| 496 | Stable functional expression of the adult subtype of human muscle acetylcholine receptor following transfection of the human rhabdomyosarcoma cell line TE671 with cDNA encoding the ε subunit | 1.9 | 51 | Citations (PDF) |
| 497 | Modulation of acetylcholine receptor function in TE671 (rhabdomyosarcoma) cells by non-AChR ligands: possible relevance to seronegative myasthenia gravis | 2.4 | 29 | Citations (PDF) |
| 498 | Cloning of cDNA Encoding Human Rapsyn and Mapping of the RAPSN Gene Locus to Chromosome 11p11.2–p11.1 | 2.7 | 17 | Citations (PDF) |
| 499 | Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis | 2.4 | 102 | Citations (PDF) |
| 500 | A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. | 9.1 | 84 | Citations (PDF) |
| 501 | CLONING AND EXPRESSION OF HUMAN S-LAMININ | 4.2 | 0 | Citations (PDF) |
| 502 | Autoimmunity to ion-channels and other proteins in paraneoplastic disorders | 5.6 | 33 | Citations (PDF) |
| 503 | A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis | 1.3 | 71 | Citations (PDF) |
| 504 | Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. | 9.1 | 140 | Citations (PDF) |
| 505 | Acquired neuromyotonia: Evidence for autoantibodies directed against K<sup>+</sup>channels of peripheral nerves | 6.6 | 388 | Citations (PDF) |
| 506 | Differences in processing of an autoantigen by DR4:Dw4.2 and DR4:Dw14.2 antigen-presenting cells | 3.5 | 7 | Citations (PDF) |
| 507 | Autoantibodies, neurotoxins and the nervous system | 1.8 | 15 | Citations (PDF) |
| 508 | An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. | 2.0 | 217 | Citations (PDF) |
| 509 | Antigen presentation by thymoma epithelial cells from myasthenia gravis patients to potentially pathogenic T cells | 2.4 | 50 | Citations (PDF) |
| 510 | IVth Congress of the International Society of Neuroimmunology Amsterdam, the Netherlands, 23–27 October 1994 | 2.4 | 1 | Citations (PDF) |
| 511 | Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen | 35.3 | 143 | Citations (PDF) |
| 512 | Immunogenicity of Human Recombinant Acetylcholine Receptor α Subunit: Cytoplasmic Epitopes Dominate the Antibody Response in four Mouse Strains | 3.1 | 7 | Citations (PDF) |
| 513 | Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line | 2.4 | 27 | Citations (PDF) |
| 514 | Passive transfer of seronegative myasthenia gravis to mice | 2.6 | 163 | Citations (PDF) |
| 515 | Response to human acetylcholine receptor α138–199: determinant spreading initiates autoimmunity to self-antigen in rabbits | 2.4 | 34 | Citations (PDF) |
| 516 | Letter to the editor | 2.4 | 1 | Citations (PDF) |
| 517 | Molecular characterisation of the human muscle nicotinic acetylcholine receptor genes | 0.7 | 0 | Citations (PDF) |
| 518 | Aetiological factors in development of myasthenia gravis | 1.7 | 36 | Citations (PDF) |
| 519 | Is the AChR α373–380 sequence a T or B cell epitope in thymoma associated-myasthenia gravis? | 0.7 | 1 | Citations (PDF) |
| 520 | Fetal acetylcholine receptor function reduced by serum from asymptomatic mother with history of fetal arthrogryposis | 0.7 | 0 | Citations (PDF) |
| 521 | Single channel properties of human muscle nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes | 0.7 | 0 | Citations (PDF) |
| 522 | Autoantibodies to voltage-gated potassium channels in acquired neuromyotonia | 0.7 | 4 | Citations (PDF) |
| 523 | “Spreading” of B cell determinants in experimental myasthenia gravis induced by acetylcholine receptor peptides | 0.7 | 0 | Citations (PDF) |
| 524 | Lambert-Eaton myasthenic syndrome IgG identifies calcium channel subtypes in neuronal cell lines | 0.7 | 0 | Citations (PDF) |
| 525 | Thymoma epithelial cells can present AChR antigens to specific T cells | 0.7 | 0 | Citations (PDF) |
| 526 | Involvement of cation channels in autoimmune disease | 4.2 | 1 | Citations (PDF) |
| 527 | Specific tolerance to an acetylcholine receptor epitope induced in vitro in myasthenia gravis CD4+ lymphocytes by soluble major histocompatibility complex class II-peptide complexes. | 9.1 | 69 | Citations (PDF) |
| 528 | Pathogenic autoimmunity to affinity-purified mouse acetylcholine receptor induced without adjuvant in BALB/c mice | 3.5 | 42 | Citations (PDF) |
| 529 | Primary structure of the human muscle acetylcholine receptor. cDNA cloning of the gamma and e subunits | 0.3 | 67 | Citations (PDF) |
| 530 | Congenital Myasthenic Syndromes | 0.7 | 27 | Citations (PDF) |
| 531 | Presentation of endogenous acetylcholine receptor epitope by an MHC class II-transfected human muscle cell line to a specific CD4+ T cell clone from a myasthenia gravis patient | 2.4 | 27 | Citations (PDF) |
| 532 | Human nicotinic acetylcholine receptor α-subunit isoforms: origins and expression | 16.2 | 23 | Citations (PDF) |
| 533 | Role of acetylcholine receptor antibody complexes in muscle in experimental autoimmune myasthenia gravis | 2.4 | 16 | Citations (PDF) |
| 534 | Stimulation of human T cells by sparse antigens captured on immunomagnetic particles | 1.5 | 20 | Citations (PDF) |
| 535 | Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome) | 35.3 | 216 | Citations (PDF) |
| 536 | Antibody-mediated neurological disease | 5.0 | 4 | Citations (PDF) |
| 537 | Role of acetylcholine receptor antibody complexes in experimental autoimmune myasthenia gravis | 6.8 | 0 | Citations (PDF) |
| 538 | Fine specificity of an AChR-reactive T cell line from a young myasthenic patient | 6.8 | 0 | Citations (PDF) |
| 539 | Acquired neuromyotonia (Isaac's syndrome): Evidence for an antibody-mediated mechanism | 2.4 | 0 | Citations (PDF) |
| 540 | Binding of acetylcholine receptor α-subunit peptides to HLA-A2 | 2.4 | 0 | Citations (PDF) |
| 541 | Selecting T cell lines in myasthenia gravis (MG) using recombinant human autoantigen | 2.4 | 0 | Citations (PDF) |
| 542 | Lectins affect ACHR function in TE671 cells: A possible model for seronegative MG plasma | 2.4 | 0 | Citations (PDF) |
| 543 | Autoimmunity to acetylcholine receptors in myasthenia gravis | 4.2 | 10 | Citations (PDF) |
| 544 | Critical role for the Val/Gly86 HLA-DR beta dimorphism in autoantigen presentation to human T cells. | 7.7 | 87 | Citations (PDF) |
| 545 | BOOK REVIWESBrain, 1990, 113, 1920-1921 | 8.9 | 0 | Citations (PDF) |
| 546 | α-Neurotoxin binding to the human nicotinic acetylcholine receptor | 4.2 | 2 | Citations (PDF) |
| 547 | A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro | 2.6 | 43 | Citations (PDF) |
| 548 | Plasma from anti-AChR Ab negative MG patients reduces Na+ influx into TE671 cells | 6.8 | 0 | Citations (PDF) |
| 549 | Motor Nerve Terminal Calcium Channels in Lambert-Eaton Myasthenic Syndrome. | 4.5 | 20 | Citations (PDF) |
| 550 | Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder | 13.4 | 166 | Citations (PDF) |
| 551 | Human muscle acetylcholine receptor: cloning and expression in <i>Escherichia coli</i> of cDNA for the α-subunit | 4.2 | 24 | Citations (PDF) |
| 552 | Epitopes on human acetylcholine receptor α-subunit: binding of monoclonal antibodies to recombinant and synthetic peptides | 4.2 | 15 | Citations (PDF) |
| 553 | Lambert-Eaton syndrome antibodies: reaction with membranes from a small cell lung cancer xenograft | 2.4 | 15 | Citations (PDF) |
| 554 | Passive transfer of myasthenia gravis by immunoglobulins: lack of correlation between AChR with antibody bound, acetylcholine receptor loss and transmission defect | 1.4 | 35 | Citations (PDF) |
| 555 | Expression of Voltage-Gated Calcium Channels in Tumor Cell Lines of Neuroectodermal or Other Origin | 4.5 | 2 | Citations (PDF) |
| 556 | Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+ flux into TE671 cell line | 2.4 | 46 | Citations (PDF) |
| 557 | Immunological and pharmacological heterogeneity of α-bungarotoxin binding sites extracted from TE671 cells | 2.4 | 25 | Citations (PDF) |
| 558 | Epitopes on Human Acetylcholine Receptor Defined by Monoclonal Antibodies and Myasthenia Gravis Sera | 3.1 | 40 | Citations (PDF) |
| 559 | Monoclonal Anti-Acetycholine Receptor Antibodies as Probes for Human Acetylcholine-Receptor in Myasthenia Gravis | 1.0 | 1 | Citations (PDF) |
| 560 | Neuroimmunology of myasthenia gravis | 4.3 | 6 | Citations (PDF) |
| 561 | Differences in Fine Specificity of Anti-Acetylcholine Receptor Antibodies between Subgroups of Spontaneous Myasthenia Gravis of Recent Onset, and of Penicillamine Induced Myasthenia | 3.1 | 12 | Citations (PDF) |
| 562 | Anti‐acetylcholine receptor antibody specificities in serum and in thymic cell culture supernatants from myasthenia gravis patients | 1.3 | 32 | Citations (PDF) |
| 563 | Disorders Affecting the Acetylcholine Receptor: Myasthenia Gravis and Congenital Myasthenia | 1.0 | 6 | Citations (PDF) |
| 564 | Expression of voltage-gated calcium channels in tumour cell lines of neuroectodermal or other origin | 2.4 | 0 | Citations (PDF) |
| 565 | Epitopes on human ACHR defined by monoclonal antibodies | 2.4 | 0 | Citations (PDF) |
| 566 | Immunological Heterogeneity and Cellular Mechanisms in Myasthenia Gravis | 4.5 | 52 | Citations (PDF) |
| 567 | Antibody Heterogeneity and Specificity in Myasthenia Gravis | 4.5 | 68 | Citations (PDF) |
| 568 | Lambert-Eaton Myasthenic Syndrome IgG: Early Morphologic Effects and Immunolocalization at the Motor Endplate | 4.5 | 15 | Citations (PDF) |
| 569 | Acetylcholine receptors in human thymic myoid cells in situ: An immunohistological study | 6.6 | 211 | Citations (PDF) |
| 570 | MYASTHENIA GRAVIS WITHOUT ACETYLCHOLINE-RECEPTOR ANTIBODY: A DISTINCT DISEASE ENTITY | 35.3 | 195 | Citations (PDF) |
| 571 | Monoclonal antibodies that distinguish between normal and denervated human acetylcholine re receptor | 2.4 | 51 | Citations (PDF) |
| 572 | Myasthenia gravis | 1.3 | 42 | Citations (PDF) |
| 573 | Monoclonal antibodies to Torpedo acetylcholine receptor. Characterisation of antigenic determinants within the cholinergic binding site | 0.3 | 36 | Citations (PDF) |
| 574 | Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. | 2.0 | 413 | Citations (PDF) |
| 575 | 4 Acetylcholine receptors and myasthenia gravis | 2.8 | 6 | Citations (PDF) |
| 576 | Acetycholine receptor antibody characteristics in myasthenia gravis☆Fractionation of α-Bungarotoxin binding site antibodies and their relationship to IgG subclass | 2.4 | 31 | Citations (PDF) |
| 577 | Immunological aspects of acetycholine receptors | 13.4 | 4 | Citations (PDF) |
| 578 | Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis. | 2.0 | 27 | Citations (PDF) |
| 579 | Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. | 7.7 | 280 | Citations (PDF) |
| 580 | Acetylcholine receptor antibody and clinical response to thymectomy in myasthenia gravis | 1.3 | 83 | Citations (PDF) |
| 581 | Anti-acetylcholine receptor antibody: Use of polyethylene glycol as an aid to precipitation of antibody-receptor complexes in determination of light chain and subclass | 1.5 | 9 | Citations (PDF) |
| 582 | Purification of anti-acetylcholine receptor antibody from patients with myasthenia gravis | 1.5 | 19 | Citations (PDF) |
| 583 | Acetylcholine Receptor Antibody: Clinical and Experimental Aspects | 1.0 | 8 | Citations (PDF) |
| 584 | ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY SYNTHESIS BY CULTURED LYMPHOCYTES IN MY ASTHENIA GRAVIS: THYMIC AND PERIPHERAL BLOOD CELL INTERACTIONS | 4.5 | 30 | Citations (PDF) |
| 585 | ANTI-ACETYLCHOLINE RECEPTOR ANTIBODY HETEROGENEITY IN DIFFERENT FORMS OF MYASTHENIA GRAVIS | 4.5 | 0 | Citations (PDF) |
| 586 | AUTOIMMUNE AETIOLOGY FOR MYASTHENIC (EATON-LAMBERT) SYNDROME | 35.3 | 321 | Citations (PDF) |
| 587 | Idiotype restriction in myasthenia gravis antibodies | 40.1 | 14 | Citations (PDF) |
| 588 | Acetylcholine receptor antibody synthesis by thymic lymphocytes | 1.3 | 160 | Citations (PDF) |
| 589 | Anti-acetylcholine receptor antibodies. | 2.0 | 138 | Citations (PDF) |
| 590 | CLINICAL, PATHOLOGICAL, HLA ANTIGEN AND IMMUNOLOGICAL EVIDENCE FOR DISEASE HETEROGENEITY IN MYASTHENIA GRAVISBrain, 1980, 103, 579-601 | 8.9 | 437 | Citations (PDF) |
| 591 | Tissue-specific antibodies in myasthenia gravis. | 1.7 | 4 | Citations (PDF) |
| 592 | Acetylcholine in Intercostal Muscle from Myasthenia Gravis Patients and in Rat Diaphragm after Blockade of Acetylcholine Receptors | 0.0 | 38 | Citations (PDF) |
| 593 | IN-VITRO SYNTHESIS OF ANTI-ACETYLCHOLINE-RECEPTOR ANTIBODY BY THYMIC LYMPHOCYTES IN MYASTHENIA GRAVIS | 35.3 | 130 | Citations (PDF) |
| 594 | ACETYLCHOLINE RECEPTORS AND END-PLATE ELECTROPHYSIOLOGY IN MYASTHENIA GRAVISBrain, 1978, 101, 345-368 | 8.9 | 108 | Citations (PDF) |
| 595 | Function of circulating antibody to acetylcholine receptor in myasthenia gravis | 1.3 | 246 | Citations (PDF) |
| 596 | Myasthenia gravis — latest developments | 8.1 | 0 | Citations (PDF) |
| 597 | Acetylcholine in human muscle | 3.2 | 31 | Citations (PDF) |
| 598 | Experimental myasthenia gravis — a new autoimmune model | 8.1 | 0 | Citations (PDF) |
| 599 | New support for autoimmune basis of myasthenia gravis | 40.1 | 1 | Citations (PDF) |
| 600 | Neuromuscular transmission after immunization against acetylcholine receptors | 3.2 | 58 | Citations (PDF) |
| 601 | Acetylcholine receptors | 2.4 | 40 | Citations (PDF) |
| 602 | Autoimmune Myasthenias 0, , 78-85 | | 0 | Citations (PDF) |
